

Sanjeev Ahuja

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3769525/publications.pdf>

Version: 2024-02-01

11
papers

263
citations

1040056

9
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

246
citing authors

#	ARTICLE	IF	CITATIONS
1	Intracellular response to process optimization and impact on productivity and product aggregates for a high-titer CHO cell process. <i>Biotechnology and Bioengineering</i> , 2018, 115, 126-138.	3.3	61
2	Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability. <i>Biotechnology and Bioengineering</i> , 2017, 114, 1264-1274.	3.3	34
3	Glutathione and thioredoxin systems contribute to recombinant monoclonal antibody interchain disulfide bond reduction during bioprocessing. <i>Biotechnology and Bioengineering</i> , 2017, 114, 1469-1477.	3.3	27
4	Development of a high yielding expression platform for the introduction of non-natural amino acids in protein sequences. <i>MAbs</i> , 2020, 12, 1684749.	5.2	27
5	Intracellular response of CHO cells to oxidative stress and its influence on metabolism and antibody production. <i>Biochemical Engineering Journal</i> , 2018, 133, 12-20.	3.6	22
6	Online control of cell culture redox potential prevents antibody interchain disulfide bond reduction. <i>Biotechnology and Bioengineering</i> , 2020, 117, 1329-1336.	3.3	20
7	Application of multivariate analysis and mass transfer principles for refinement of a 3-L bioreactor scale-down model-when shake flasks mimic 15,000-L bioreactors better. <i>Biotechnology Progress</i> , 2015, 31, 1370-1380.	2.6	19
8	Perfusion reduces bispecific antibody aggregation via mitigating mitochondrial dysfunction-induced glutathione oxidation and ER stress in CHO cells. <i>Scientific Reports</i> , 2020, 10, 16620.	3.3	17
9	Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region. <i>MAbs</i> , 2020, 12, 1779974.	5.2	16
10	Addressing Patient to Patient Variability for Autologous CAR T Therapies. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1871-1876.	3.3	12
11	Impact of enzymatic reduction on bivalent bispecific antibody fragmentation and loss of product purity upon reoxidation. <i>Biotechnology and Bioengineering</i> , 2020, 117, 1063-1071.	3.3	8